The University of Southampton
University of Southampton Institutional Repository

Imatinib for systemic mast-cell disease

Imatinib for systemic mast-cell disease
Imatinib for systemic mast-cell disease
Imatinib has shown to be effective against malignant disease driven by ckit. We prospectively treated 12 adults with symptomatic systemic mast-cell disease at a dose of either 100 mg or 400 mg per day. Of the ten patients who we could assess for response, five (50%) had a measurable response to the drug, four of whom had important mast-cell cytoreduction and two who had complete clinical and histological remission. In the five patients with eosinophilia, three had complete clinical and haematological remission. The other two, who did not respond to treatment, were the only patients with the ckit D816V mutation. Our results suggest that imatinib either inhibits the growth-promoting role of wild type ckit, or targets an oncogenic kinase.
mutation, proteins, antagonists & inhibitors, disease, treatment outcome, protein-tyrosine kinase, role, therapeutic use, eosinophilia, patients, protein, drug therapy, systemic, proto-oncogene proteins c-kit, antineoplastic agents, drug effects, enzymology, drug administration schedule, piperazines, mastocytosis, genetics, proto-oncogene proteins, adult, pyrimidines, humans
0140-6736
535-536
Pardanani, A.
670cc45b-ebfa-4361-8a0b-4f18da0e9d04
Elliott, M.
72144b37-250f-4bf8-8454-0c17e1318bfa
Reeder, T.
ccf87c71-0d7b-4c98-9f8a-b88e9e57557c
Li, C.Y.
c5df76d4-314b-42ef-85b8-813767bcecbf
Baxter, E.J.
f6d9776c-fb5c-43ab-ac64-d1174afcd11a
Cross, N.C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Tefferi, A.
0a535985-a168-432a-8fcc-dfc5448f5e2b
Pardanani, A.
670cc45b-ebfa-4361-8a0b-4f18da0e9d04
Elliott, M.
72144b37-250f-4bf8-8454-0c17e1318bfa
Reeder, T.
ccf87c71-0d7b-4c98-9f8a-b88e9e57557c
Li, C.Y.
c5df76d4-314b-42ef-85b8-813767bcecbf
Baxter, E.J.
f6d9776c-fb5c-43ab-ac64-d1174afcd11a
Cross, N.C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Tefferi, A.
0a535985-a168-432a-8fcc-dfc5448f5e2b

Pardanani, A., Elliott, M., Reeder, T., Li, C.Y., Baxter, E.J., Cross, N.C.P. and Tefferi, A. (2003) Imatinib for systemic mast-cell disease. The Lancet, 362 (9383), 535-536. (doi:10.1016/S0140-6736(03)14115-3).

Record type: Article

Abstract

Imatinib has shown to be effective against malignant disease driven by ckit. We prospectively treated 12 adults with symptomatic systemic mast-cell disease at a dose of either 100 mg or 400 mg per day. Of the ten patients who we could assess for response, five (50%) had a measurable response to the drug, four of whom had important mast-cell cytoreduction and two who had complete clinical and histological remission. In the five patients with eosinophilia, three had complete clinical and haematological remission. The other two, who did not respond to treatment, were the only patients with the ckit D816V mutation. Our results suggest that imatinib either inhibits the growth-promoting role of wild type ckit, or targets an oncogenic kinase.

This record has no associated files available for download.

More information

Published date: 2003
Keywords: mutation, proteins, antagonists & inhibitors, disease, treatment outcome, protein-tyrosine kinase, role, therapeutic use, eosinophilia, patients, protein, drug therapy, systemic, proto-oncogene proteins c-kit, antineoplastic agents, drug effects, enzymology, drug administration schedule, piperazines, mastocytosis, genetics, proto-oncogene proteins, adult, pyrimidines, humans
Organisations: Human Genetics

Identifiers

Local EPrints ID: 60113
URI: http://eprints.soton.ac.uk/id/eprint/60113
ISSN: 0140-6736
PURE UUID: 74244526-d85e-4f4e-b304-a1f53d6f67b4
ORCID for N.C.P. Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 05 Sep 2008
Last modified: 16 Aug 2024 01:38

Export record

Altmetrics

Contributors

Author: A. Pardanani
Author: M. Elliott
Author: T. Reeder
Author: C.Y. Li
Author: E.J. Baxter
Author: N.C.P. Cross ORCID iD
Author: A. Tefferi

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×